Approval · Notice of Compliance 13643 · 2012
BROMOCRIPTINE: Notice of Compliance 13643
Issued September 7, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13643
- Date
- September 7, 2012
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Prolactin Inhibitor; Growth Hormons Suppressant in Acromegaly, Adjunctive Medication in Parkinson's Disease
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BROMOCRIPTINE | 02230454 | Marketed |
| BROMOCRIPTINE | 02087324 | Marketed |
Medicinal ingredients
- BROMOCRIPTINE MESYLATE 5 MG per CAP
- BROMOCRIPTINE MESYLATE 2.5 MG per TAB